Ardena Acquires Idifarma From Suanfarma

Ardena acquires Idifarma, adding spray drying technology and high potency capabilities.

Ardena—a European contract development and manufacturing organization (CDMO) with services spanning the full development life cycle—announced in a Sept. 1, 2021, press release that it has acquired Idifarma, a contract manufacturer of niche and highly-potent generic and innovative drugs that’s based in Pamplona, Spain. With the acquisition, there are now seven Ardena facilities in Europe, including its headquarters in Ghent, Belgium, three sites in the Netherlands, and two sites in Northern Europe (Sweden and Latvia).

Established in 2011, Idifarma offers various services spanning the full pharma lifecycle for highly potent drugs. Its capabilities include a platform for an accelerated path to clinic and spray drying processes that resolve solubility issues.

“At Ardena, our goal is to become a single source contractor offering an integrated set of services to meet chemical, pharmaceutical and bio-analytical needs that arise throughout the clinical supply chain, from lab to patient. This is the main driver of our M&A strategy,” Harry Christiaens, CEO of Ardena, said in a company press release. “We’re delighted to welcome Idifarma who share the science-led approach needed to deliver valuable and integrated solutions for our biopharma customers globally. The combination of Idifarma and Ardena will also create potential to accelerate growth at the Pamplona facility.”

Source: Ardena